Holen Sie sich die Stockscreener-App
29.97
1.15%
-0.35
Handel nachbörslich:
29.97
Schlusskurs vom Vortag:
$30.32
Offen:
$30.62
24-Stunden-Volumen:
392.46K
Relative Volume:
0.47
Marktkapitalisierung:
$1.72B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.44M
KGV:
-13.50
EPS:
-2.22
Netto-Cashflow:
$-105.32M
1W Leistung:
+6.20%
1M Leistung:
+10.51%
6M Leistung:
-19.84%
1J Leistung:
-31.29%
1-Tages-Spanne:
$29.78
$31.72
1-Wochen-Bereich:
$27.64
$31.72
52-Wochen-Spanne:
$23.50
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(628) 229-9277
Adresse
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Vergleichen Sie GPCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
29.97 | 1.72B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Structure Therapeutics (NASDAQ:GPCR) Trading 8.3% HigherShould You Buy? - MarketBeat
JPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Air T (NASDAQ:AIRT) Shares Cross Below 200-Day Moving Average – What’s Next? - Defense World
JPMorgan Chase & Co. Acquires 25,500 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Analysts Issue Forecasts for Kits Eyecare Q4 Earnings - Defense World
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
Morningstar Mobile - Morningstar
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - MarketBeat
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts - BNN Bloomberg
GAMMA Investing LLC Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Schrödinger Secures $150M Novartis Deal, Advances Three Clinical Programs for 2025 - StockTitan
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year LowShould You Sell? - MarketBeat
GPCR stock touches 52-week low at $25.89 amid market challenges - Investing.com Canada
Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpHere's What Happened - MarketBeat
Stifel analysts initiate Structure Therapeutics stock with buy rating By Investing.com - Investing.com Canada
State Street Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year LowShould You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading 5.6% HigherStill a Buy? - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Principal Financial Group Inc. - MarketBeat
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - MedCity News
Barclays PLC Boosts Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Time to Buy? - Defense World
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. - Barron's
Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6%Still a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Franklin Resources Inc. Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral obesity drug stock shows promise amid fierce competition - Investing.com
Here's Why VKTX Stock Plummeted 18% on Wednesday - Yahoo Finance
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year LowWhat's Next? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from JMP Securities - MarketBeat
Merck snags Chinese obesity drug in nearly $2 billion deal - Fortune
Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Consensus PT from Brokerages - Defense World
Structure Therapeutics Advances Obesity Treatment Candidate - TipRanks
Structure Therapeutics Unveils Breakthrough Oral Obesity Drug, First-in-Class Amylin Agonist Shows Promise - StockTitan
Mcewen Mining Inc (MUX-N) QuotePress Release - The Globe and Mail
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - MarketBeat
Structure Therapeutics' SWOT analysis: oral GLP-1 stock faces fierce competition - Investing.com
Market Factors: The biggest debatesand risksfor investors looking to outperform in 2025 - The Globe and Mail
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Average PT from Analysts - MarketBeat
Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Y Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):